BioSpace News Archive

First fiscal quarter revenues of $5.315 billion grew 25.8% on a reported basis. On a currency-neutral basis, revenues increased 24.3%.

LabTwin GmbH, a company developing the world’s first voice and AI-powered digital lab assistant, announced an official collaboration with Covestro AG.

Vizient, Inc. announced it is again expanding the product portfolio for its Novaplus Enhanced Supply Program.

Because Alzheimer’s disease is such a serious concern for seniors, any advocacy group’s recommendations for a drug company’s proposed therapy must be science-based and above reproach, says Leslie Norins, MD, PhD, FIDSA, CEO of Alzheimer’s Germ Quest.

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, February 12, 2021 at 3:00 p.m. Eastern Standard Time.

Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 18, 2021 at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2020, recent business developments, financial outlook for full year 2021, and revenue guidance for the first quarter of 2021.

Phoenix Molecular Designs (PhoenixMD), an industry leader in the development of precise cancer therapeutics focusing on first-in-class RSK kinase inhibitors, today announced the appointment of Dr. Alan Ashworth PhD, FRS to their Advisory Board as a Scientific Advisor.

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced today the Company’s Board of Directors has authorized a 10.7% increase in its quarterly dividend from $0.56 to $0.62 per share.

AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021 first quarter ended December 31, 2020, revenue increased 9.7 percent year-over-year to $52.5 billion.

ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study “Combined Metabolic Cofactor Supplementation Reduces Liver Fat in Nonalcoholic Fatty Liver Disease” were published on Cell Press Sneak Peek, a preprint publication website for papers under review by Cell Press Journals